JERUSALEM, December 29, 2021 / PRNewswire / – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on the development, manufacture and commercialization of innovative products for the prevention and treatment of infectious diseases and other diseases, today announced the closing of a subscribed public offering of 4 144,068 American Depositary Shares (“ADS”) at a public offer price of $ 2.36 by ADS for gross proceeds accruing to the Company of approximately $ 9.8 million in total, including the successful execution of the entire over-allotment, before deduction of subscription discounts and other offering costs. Each ADS represents 40 ordinary shares of BiondVax.
Amir Reichman, CEO of BiondVax, commented, “This successful offering is an important event for BiondVax as it provides us with increased capital to fund our recently announced Nanoscale Antibody (NanoAb) program, conducted in collaboration with the world-renowned Max Planck Institute. Development of an innovative COVID-19 NanoAb therapy that has significant potential competitive advantages over existing therapies has already started, and next month we plan to sign a broader collaboration for the development of additional NanoAbs to treat diseases with significant unmet medical needs and attractive business opportunities. I want to thank everyone who has supported our recent successes and warmly welcome new investors to our story.“
BiondVax intends to use the net proceeds from this offering for the advancement of its recently announced Nanoscale Antibody (NanoAb) development program as well as for general corporate purposes, including, but not limited to. ” limit, working capital, research and development activities, regulatory matters, capital investment or other related purposes. It may also use a portion of any net proceeds to license, invest in or acquire any businesses, assets or technologies that it deems complementary to its business purpose, although it has no current commitment or agreement to. this regard.
Aegis Capital Corp. acted as the only accounting manager of the offer.
The ADSs described above are offered by the Company pursuant to a “shelf” registration statement on Form F-3 (333-240189) filed with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on Aug 10, 2020. A final prospectus supplement relating to the Offer and describing the terms of the Offer has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the Final Prospectus Supplement and the accompanying prospectus relating to the Offer can also be obtained from Aegis Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th Floor, New York, New York State 10019, by email to [email protected], or by phone at (212) 813-1010.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described in this document, and there will be no sale of such securities in any jurisdiction in which such an offer, solicitation or sale would be illegal before registration. or qualification under securities laws of such jurisdiction.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on the development, manufacture and commercialization of innovative products for the prevention and treatment of infectious and other diseases. Since its inception, the company has completed eight clinical trials, including a Phase 3 trial in seven countries, with 12,400 participants, of its vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceuticals. With highly experienced leadership in the pharmaceutical industry, BiondVax aims to develop a pipeline of diversified and commercially viable products and platforms, starting with an innovative pipeline of nanoscale antibodies (NanoAb). For more information, please visit www.biondvax.com.
Society: Joshua E. Phillipson | +972 8 930 2529 | [email protected]
Investor Relations: Kenny Green | +1 212 378 8040 | [email protected]
The Private Securities Litigation Reform Act of 1995 provides a safe haven for forward-looking statements made by or on our behalf. This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, but not limited to, statements regarding BiondVax’s ability to complete the offer, expected gross proceeds, expected closing date of the offer and intended use of the proceeds from the offer. Any statement that is not historical in nature is a forward-looking statement and can be identified by the use of words and phrases such as “expects”, “anticipates”, “believes”, “will”, “in”. will likely result “,” will continue “,” considering “,” potential “,” promising “and similar expressions. These statements are based on the current expectations and beliefs of management and are subject to a number of risks, risks and assumptions. uncertainties and assumptions that could cause actual results to differ materially from those described in forward-looking statements, including the risk factors described under the heading “Risk Factors” set forth in the Company’s reports filed with the SEC from time to time. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. BiondVax assumes no obligation to publicly update any forward-looking statement. e, whether as a result of new information, future events or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described here should not be taken as a complete list.
SOURCE BiondVax Pharmaceuticals Ltd.